Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy
Open Access
- 1 May 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Objective We aimed to investigate whether wearing-off symptoms at the end of the natalizumab dosing interval were associated with clinical and demographic patient characteristics or natalizumab receptor occupancy (RO) on leukocytes. Methods In this cross-sectional study of 40 patients with relapsing-remitting MS (RRMS) receiving natalizumab at the Department of Neurology, Haukeland University Hospital, we recorded clinical and demographic data including age, body mass index (BMI), working status, smoking habits, disease characteristics, treatment duration, vitamin D levels, and wearing-off symptoms. We quantified neurofilament light chain in serum and measured natalizumab RO in leukocyte subtypes by high-parameter mass cytometry. Associations with wearing-off symptoms were analyzed. Results Eight (20.0%) patients who reported regular occurrence of wearing-off symptoms, 9 (22.5%) who sometimes had wearing-off symptoms, and 23 (57.5%) who did not have wearing-off symptoms were evaluated. Patients who regularly had wearing-off symptoms had lower natalizumab RO than patients who reported having such symptoms sometimes or never. The former group also had higher BMI and higher frequency of sick leave. High BMI was associated with low RO. No other demographic or disease characteristics were associated with the phenomenon. Conclusions Low RO may explain the wearing-off phenomenon observed in some patients with RRMS treated with natalizumab, and high BMI may be the underlying cause.Keywords
This publication has 24 references indexed in Scilit:
- Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosingNeurology, 2019
- Neurofilament Light Chain as a Biomarker in Multiple SclerosisFrontiers in Neurology, 2019
- Monitoring CD49d Receptor Occupancy: A Method to Optimize and Personalize Natalizumab Therapy in Multiple Sclerosis PatientsCytometry Part B: Clinical Cytometry, 2017
- Multiple Sclerosis Symptom Recrudescence at the End of the Natalizumab Dosing CycleInternational Journal of MS Care, 2014
- The who's who of T‐cell differentiation: Human memory T‐cell subsetsEuropean Journal of Immunology, 2013
- Risk of Natalizumab-Associated Progressive Multifocal LeukoencephalopathyThe New England Journal of Medicine, 2012
- Mass Cytometry: Technique for Real Time Single Cell Multitarget Immunoassay Based on Inductively Coupled Plasma Time-of-Flight Mass SpectrometryAnalytical Chemistry, 2009
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2006
- The Fatigue Severity ScaleArchives of Neurology, 1989
- Rating neurologic impairment in multiple sclerosisNeurology, 1983